Non-small Cell Lung Cancer Stage III Clinical Trial
Official title:
A Prospective Study on the Efficacy, Safety and Immune Effects of Dose-painting Radiation for Locally Advanced Non-small Cell Lung Cancer(LA-NSCLC)
The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer.
The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer. The primary endpoint is PFS. Secondary points contains ORR, OS, HRQoL, and safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557552 -
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer
|
N/A | |
| Active, not recruiting |
NCT04765709 -
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06449313 -
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06031597 -
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
|
Phase 3 | |
| Recruiting |
NCT04728724 -
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT06015815 -
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
|
||
| Completed |
NCT03728556 -
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT02434081 -
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
| Completed |
NCT03550482 -
Oncoxin® and Quality of Life in Cancer Patients
|
Phase 4 | |
| Recruiting |
NCT05398094 -
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
|
Phase 2 | |
| Completed |
NCT02418234 -
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
|
N/A | |
| Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05414630 -
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT04941365 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
N/A | |
| Not yet recruiting |
NCT06463665 -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)
|
Phase 2 | |
| Active, not recruiting |
NCT04699721 -
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC
|
Phase 1 |